# Aveanna Healthcare Holdings, Inc.: overview

AVAH · Nasdaq · CIK 1832332 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jan 1

Pages: [Overview](/companies/avah.md) · [Financials](/companies/avah/financials.md) · [Filings](/companies/avah/filings.md) · [Insiders](/companies/avah/insiders.md)

Latest reported revenue: [$670.5m](/filings/0001193125-26-347842.md) for Q2 FY2026, three months to 2026-07-04, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-347842).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2026-01-03) | Q1 FY2026 (2026-04-04) | Q2 FY2026 (2026-07-04) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [509](/filings/0001193125-25-267978.md) | [520 d](/filings/0001193125-26-115851.md) | [559](/filings/0001193125-26-222736.md) | [590](/filings/0001193125-26-347842.md) | [622](/filings/0001193125-25-267978.md) | [662 d](/filings/0001193125-26-115851.md) | [648](/filings/0001193125-26-222736.md) | [670](/filings/0001193125-26-347842.md) |
| Gross margin | % | [31.4%](/filings/0001193125-25-267978.md) | [33.0% d](/filings/0001193125-26-115851.md) | [32.8%](/filings/0001193125-26-222736.md) | [35.8%](/filings/0001193125-26-347842.md) | [32.6%](/filings/0001193125-25-267978.md) | [32.2% d](/filings/0001193125-26-115851.md) | [31.7%](/filings/0001193125-26-222736.md) | [32.6%](/filings/0001193125-26-347842.md) |
| Operating margin | % | [6.7%](/filings/0001193125-25-267978.md) | [8.8% d](/filings/0001193125-26-115851.md) | [9.3%](/filings/0001193125-26-222736.md) | [13.6%](/filings/0001193125-26-347842.md) | [8.6%](/filings/0001193125-25-267978.md) | [10.7% d](/filings/0001193125-26-115851.md) | [10.7%](/filings/0001193125-26-222736.md) | [11.9%](/filings/0001193125-26-347842.md) |
| Net margin | % | [(8.4%)](/filings/0001193125-25-267978.md) | [5.6% d](/filings/0001193125-26-115851.md) | [0.9%](/filings/0001193125-26-222736.md) | [4.6%](/filings/0001193125-26-347842.md) | [2.3%](/filings/0001193125-25-267978.md) | [27.0% d](/filings/0001193125-26-115851.md) | [6.4%](/filings/0001193125-26-222736.md) | [6.0%](/filings/0001193125-26-347842.md) |
| Diluted EPS | $ per share | [(0.22)](/filings/0001193125-25-267978.md) | not reported | [0.03](/filings/0001193125-26-222736.md) | [0.13](/filings/0001193125-26-347842.md) | [0.06](/filings/0001193125-25-267978.md) | not reported | [0.19](/filings/0001193125-26-222736.md) | [0.18](/filings/0001193125-26-347842.md) |
| Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2022-01-01) | FY2022 (2022-12-31) | FY2023 (2023-12-30) | FY2024 (2024-12-28) | FY2025 (2026-01-03) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,679](/filings/0000950170-23-008309.md) | [1,788](/filings/0000950170-24-031321.md) | [1,895](/filings/0000950170-25-038504.md) | [2,025](/filings/0001193125-26-115851.md) | [2,433](/filings/0001193125-26-115851.md) |
| Gross margin | % | [32.3%](/filings/0000950170-23-008309.md) | [30.9%](/filings/0000950170-24-031321.md) | [31.4%](/filings/0000950170-25-038504.md) | [31.4%](/filings/0001193125-26-115851.md) | [33.3%](/filings/0001193125-26-115851.md) |
| Operating margin | % | [(2.2%)](/filings/0000950170-23-008309.md) | [(35.9%)](/filings/0000950170-24-031321.md) | [0.4%](/filings/0000950170-25-038504.md) | [6.9%](/filings/0001193125-26-115851.md) | [10.5%](/filings/0001193125-26-115851.md) |
| Net margin | % | [(7.0%)](/filings/0000950170-23-008309.md) | [(37.0%)](/filings/0000950170-24-031321.md) | [(7.1%)](/filings/0000950170-25-038504.md) | [(0.5%)](/filings/0001193125-26-115851.md) | [9.2%](/filings/0001193125-26-115851.md) |
| Diluted EPS | $ per share | [(0.69)](/filings/0000950170-23-008309.md) | [(3.57)](/filings/0000950170-24-031321.md) | [(0.71)](/filings/0000950170-25-038504.md) | [(0.06)](/filings/0001193125-26-115851.md) | [1.05](/filings/0001193125-26-115851.md) |
| Free cash flow | $m | [(27.3)](/filings/0000950170-23-008309.md) | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/avah/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Bain Capital Investors LLC](/funds/1040508.md) | 2026-06-30 | $699.3m | 81,600,880 |  | Unchanged |
| [J.H. Whitney Equity Partners VII, LLC](/funds/1567459.md) | 2026-06-30 | $231.9m | 27,061,967 |  | Reduced −9,180,664 |
| [Nut Tree Capital Management, LP](/funds/1661655.md) | 2026-06-30 | $110.7m | 12,922,649 |  | Unchanged |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $63.5m | 7,410,053 |  | Added +1,909,141 |
| [Ophir Asset Management Pty Ltd](/funds/1844640.md) | 2026-06-30 | $43.7m | 5,100,000 |  | New +5,100,000 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $31.5m | 3,673,218 |  | Reduced −301,601 |
| [BRAIDWELL LP](/funds/1920938.md) | 2026-06-30 | $26.3m | 3,065,106 |  | Added +861,600 |
| [Boston Partners](/funds/1386060.md) | 2026-06-30 | $24.9m | 2,870,979 |  | Added +46,905 |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $19.6m | 2,285,756 |  | Added +2,008,806 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $19.3m | 2,257,684 |  | Added +923,310 |

## Recent filings

[All 411 filings](/companies/avah/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-02 | 20:55 ET | [8-K](/filings/0001193125-26-412540.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-412540 |
| 2026-08-24 | 20:29 ET | [8-K](/filings/0001193125-26-363654.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-363654 |
| 2026-08-13 | 11:00 ET | [10-Q](/filings/0001193125-26-347842.md) | Quarterly report, period 2026-07-04 | 0001193125-26-347842 |
| 2026-08-13 | 11:00 ET | [8-K](/filings/0001193125-26-347840.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-347840 |
| 2026-08-13 | 11:00 ET | [8-K](/filings/0001193125-26-347839.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-347839 |
| 2026-08-07 | 20:43 ET | [8-K](/filings/0001193125-26-340409.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-340409 |
| 2026-06-02 | 11:30 ET | [8-K](/filings/0001193125-26-252511.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-252511 |
| 2026-05-29 | 20:15 ET | [8-K](/filings/0001193125-26-248323.md) | 5.07 Shareholder vote results | 0001193125-26-248323 |
| 2026-05-28 | 12:00 ET | [8-K](/filings/0001193125-26-243028.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-243028 |
| 2026-05-15 | 12:30 ET | [8-K](/filings/0001193125-26-225430.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-225430 |

## Latest annual report

[Form 10-K for the fiscal year ended Jan 3, 2026](/filings/0001193125-26-115851.md), filed Mar 19, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1832332
- Tickers: AVAH
- Exchange: Nasdaq
- SIC code: 8082 Services-Home Health Care Services
- State of incorporation: DE
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.